SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GelTex Pharmaceuticals (GELX)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: NY0001 who wrote (44)10/29/1997 12:43:00 AM
From: James Silverman   of 127
 
Interesting stuff Neuro.
One point is that GELX isn't trying to pretend that cholestagel as a stand alone is as effective as statins, which is a big reason for their recently released combo trial which is smart on their part. Their drug is an improved bile acid sequestrant that is apparently more efficacious with lessened side effects than exising _bile acid sequestrants_. It is not as effective as statins in lowering cholesterol levels. Statins are highly effective at lowering LDL and have been proven to save thousands of lives. At best cholestagel will be a niche player or a drug used in combo as far as I can tell.

I'd be really surprised if GELX has any interest in food additives. One interesting drug delivery firm that is in that area is FUSE. As far as niche pharmaceuticals that may get in that area, FUSE may be your best bet as far as combo drug/neutraceuticals goes.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News